W
Walter Berger
Researcher at Medical University of Vienna
Publications - 396
Citations - 16667
Walter Berger is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Cell culture. The author has an hindex of 63, co-authored 359 publications receiving 14045 citations. Previous affiliations of Walter Berger include University of Vienna & Université libre de Bruxelles.
Papers
More filters
Journal ArticleDOI
KP1019, a new redox-active anticancer agent--preclinical development and results of a clinical phase I study in tumor patients.
Christian G. Hartinger,Christian G. Hartinger,Michael A. Jakupec,Stefanie Zorbas-Seifried,Michael Groessl,Alexander E. Egger,Walter Berger,Haralabos Zorbas,Paul J. Dyson,Bernhard K. Keppler +9 more
TL;DR: The experimental evidence for the proposed mode of action of this coordination compound is discussed, including transport into the cell via the transferrin cycle and activation by reduction.
Journal ArticleDOI
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Dominik Sturm,Dominik Sturm,Brent A. Orr,Umut H. Toprak,Volker Hovestadt,David T.W. Jones,David Capper,David Capper,Martin Sill,Ivo Buchhalter,Paul A. Northcott,Irina Leis,Marina Ryzhova,Christian Koelsche,Christian Koelsche,Elke Pfaff,Elke Pfaff,Sariah Allen,Gnanaprakash Balasubramanian,Barbara C. Worst,Barbara C. Worst,Kristian W. Pajtler,Sebastian Brabetz,Pascal Johann,Pascal Johann,Felix Sahm,Felix Sahm,Jüri Reimand,Jüri Reimand,Alan Mackay,Diana Carvalho,Marc Remke,Joanna J. Phillips,Arie Perry,Cynthia Cowdrey,Rachid Drissi,Maryam Fouladi,Felice Giangaspero,Maria Łastowska,Wiesława Grajkowska,Wolfram Scheurlen,Torsten Pietsch,Christian Hagel,Johannes Gojo,Daniela Lötsch,Walter Berger,Irene Slavc,Christine Haberler,Anne Jouvet,Stefan Holm,Silvia Hofer,Marco Prinz,Catherine Keohane,Iris Fried,Christian Mawrin,David Scheie,Bret C. Mobley,Matthew Schniederjan,Mariarita Santi,Anna Maria Buccoliero,Sonika Dahiya,Christof M. Kramm,André O. von Bueren,Katja von Hoff,Stefan Rutkowski,Christel Herold-Mende,Michael C. Frühwald,Till Milde,Till Milde,Martin Hasselblatt,Pieter Wesseling,Pieter Wesseling,Jochen Rößler,Ulrich Schüller,Martin Ebinger,Jens Schittenhelm,Stephan Frank,Rainer Grobholz,Istvan Vajtai,Volkmar Hans,Reinhard Schneppenheim,Karel Zitterbart,V. Peter Collins,Eleonora Aronica,Pascale Varlet,Stéphanie Puget,Christelle Dufour,Jacques Grill,Dominique Figarella-Branger,Marietta Wolter,Martin U. Schuhmann,Tarek Shalaby,Michael A. Grotzer,Timothy E. Van Meter,Camelia M. Monoranu,Jörg Felsberg,Guido Reifenberger,Matija Snuderl,Lynn Ann Forrester,Jan Koster,Rogier Versteeg,Richard Volckmann,Peter van Sluis,Stephan Wolf,Tom Mikkelsen,Amar Gajjar,Kenneth Aldape,Andrew S. Moore,Michael D. Taylor,Chris Jones,Nada Jabado,Matthias A. Karajannis,Roland Eils,Matthias Schlesner,Peter Lichter,Andreas von Deimling,Andreas von Deimling,Stefan M. Pfister,Stefan M. Pfister,David W. Ellison,Andrey Korshunov,Andrey Korshunov,Marcel Kool +122 more
TL;DR: It is demonstrated that a significant proportion of institutionally diagnosed CNS-PNETs display molecular profiles indistinguishable from those of various other well-defined CNS tumor entities, facilitating diagnosis and appropriate therapy for patients with these tumors.
Journal ArticleDOI
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl,Petra Heffeter,Christian R. Kowol,Michael A. Jakupec,Walter Berger,Bernhard K. Keppler +5 more
TL;DR: Taken together, KP1019 and NKP-1339 are promising drug candidates, and especially the very limited side effects observed so far in clinical phase I trials seem to be a major advantage of this class of ruthenium drugs as compared to other chemotherapeutics and targeted anticancer compounds.
Journal ArticleDOI
Anticancer activity of metal complexes: involvement of redox processes.
Ute Jungwirth,Christian R. Kowol,Bernhard K. Keppler,Christian G. Hartinger,Walter Berger,Petra Heffeter +5 more
TL;DR: The aim of this review is to highlight specific interactions of metal-based anticancer drugs with the cellular redox homeostasis and to explain this behavior by considering chemical properties of the respective anticancer metal complexes currently either in (pre)clinical development or in daily clinical routine in oncology.
Journal ArticleDOI
Structure–activity relationships for ruthenium and osmium anticancer agents – towards clinical development
Samuel M. Meier-Menches,Samuel M. Meier-Menches,Christopher Gerner,Walter Berger,Walter Berger,Christian G. Hartinger,Bernhard K. Keppler +6 more
TL;DR: Global structure-activity relationships are discussed for ruthenium and osmium metallodrugs with respect to in vitro antiproliferative/cytotoxic activity and in vivo tumor-inhibiting properties, as well as pharmacokinetics.